Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial-Reference-Cited by-同舟云学术

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial

Published:2017-10 Issue: Volume:131 Page:27-34
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Crim Courtney,Calverley Peter M.A.,Anderson Julie A.,Holmes Andrew P.,Kilbride Sally,Martinez Fernando J.,Brook Robert D.,Newby David E.,Yates Julie C.,Celli Bartolomé R.,Vestbo Jørgen

Funder

North Carolina GlaxoSmithKline Foundation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference31 articles.

1. World Health Organization. The top 10 causes of death. The 10 leading causes of death in the world, 2000 and 2012;[accessed 2016 March 24]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en.

2. The burden of community-acquired pneumonia in seniors: results of a population-based study;Jackson;Clin. Inf. Dis.,2004

3. Risk factors for death and hospitalisation from pneumonia. A prospective study of a general population;Lange;Eur. Respir. J.,1995

4. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results;Crim;Eur. Respir. J.,2009

5. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind randomized study;Sharafkhaneh;Respir. Med.,2012

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Obstructive Pulmonary Disease in Heart Failure: Challenges in Diagnosis and Treatment for HFpEF and HFrEF;Current Heart Failure Reports;2024-03-28

2. Effect of YuPingFeng granules on clinical symptoms of stable COPD: study protocol for a multicenter, double-blind, and randomized controlled trial;BMC Complementary Medicine and Therapies;2024-01-08

3. A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom;Expert Review of Vaccines;2023-09-11

4. Fluticasone Furoate/Vilanterol Use Trends and Characteristics in Patients With Obstructive Airway Disease: A Real-World Study of 10,374 Patients From India;Cureus;2023-02-09

5. Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions;Expert Opinion on Drug Safety;2021-11-26